• WEBINAR PRESENTED BY JEFF FILL, ELI LILLY
  • Wednesday, July 15th 11 AM EDT
    Please join us - Register here today!
  • Analytical Validation of CTC Enumeration using the RareCyte Platform and Implementation in a Global Clinical Trial
Precision Biology solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics

News & Events

Accurate Spike-in of Circulating Tumor Cells into Blood Samples is Essential for Reliable Analysis in Oncology Applications
more →

CHI Webinar with speakers Jeff Fill, Eli Lilly, and Arturo Ramirez, RareCyte
info and registration →

RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay
more →

Highlight

RareCyte expands its world-class liquid biopsy imaging and retrieval platform to support tissue workflows with the new CyteFinder II Instruments.

more →

RarePlex CTC Developer Staining Kit enables custom CTC assay development by providing the ability to add up to two biomarkers-of-interest to the CTC base detection assay.

more →

Pharma Programs

“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”

   – Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company

more →